Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eupatoriopicrin (EPD) is a natural germacranolide-type sesquiterpene lactone primarily isolated from the plant *Eupatorium cannabinum* (hemp-agrimony). It is recognized for its potent cytotoxic and anti-inflammatory properties. In oncological research, particularly concerning ovarian cancer, EPD has demonstrated significant anti-tumor activity and exhibits synergistic effects when combined with standard chemotherapeutic agents like cisplatin and paclitaxel. Its mechanism of action involves the induction of apoptosis through the activation of the mitochondrial pathway (caspase-3 and caspase-9), inhibition of the NF-κB signaling pathway, and the generation of reactive oxygen species (ROS). Additionally, eupatoriopicrin has been shown to induce cell cycle arrest in the G2/M phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on eupatoriopicrin.